

AlphaRx Retains Dr. Lee Simon, Former FDA Analgesic, Anti-inflammatory and Ophthalmologic Drug Products Division Director, As Consultant

Thursday June 24, 8:00 am ET

MARKHAM, ON, June 24 /CNW/ - AlphaRx Inc. (OTCBB: [ALRX](#) - [News](#)) is pleased to announce that, in preparation of entering clinical trials for Indaflex(TM), they have retained the services of prominent consultant Dr. Lee Simon. Dr. Simon is a clinical and regulatory expert with significant experience in developing new drugs and will advise the Company in Indaflex(TM) clinical program development.

Dr. Simon has had a distinguished career and many years of experience in bringing new pharmaceuticals to market. In addition, Dr. Simon served as a consultant for more than a decade with various well-known firms such as the American Hospital Formulary, Division of Drugs and Toxicology (American Medical Association), FDA Compliance Division, GD Searle, Eli Lilly, Aventis and the FDA Arthritis Advisory Committee.

"Dr. Simon has extraordinary experience in drug development both at FDA and with big pharmaceutical companies. Specifically, his experience in analgesics and arthritis provides us leverage in advancing our Indaflex(TM) clinical program," stated President & CEO of AlphaRx Inc., Mr. Michael Lee.

About Indaflex(TM)

Indaflex is AlphaRx's topical NSAID (Non-Steroidal Anti-inflammatory Drug) formulation intended to start clinical development soon for use in the treatment symptoms of arthritis. Arthritis is the most common chronic condition in North America and afflicts an estimated 10% of the world's population. Indaflex's active ingredient, Indomethacin, has long-standing and proven clinical treatment records. With AlphaRx's enhanced proprietary delivery system, the company believes its clinical effectiveness will be significantly enhanced compared to other topical preparations. Topical Indaflex delivery, the company hopes may circumvent the significant GI side-effects found with orally ingested NSAID's.

About AlphaRx Inc.

AlphaRx is an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. AlphaRx's broad product pipeline consists of drugs with a strong commercial potential that can be dramatically improved through the application of its proprietary BCD(TM) drug delivery technology. For more information, please visit <http://www.alpharx.com>.

FORWARD LOOKING STATEMENTS:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.